The Washington Legal Foundation on Monday backed Allergan PLC in a fight over class certification, telling the First Circuit that a Massachusetts federal judge shouldn’t have certified a class of insurers who paid for an ulcerative colitis drug without parties tied to each state involved in the product-hopping suit.
The First Circuit on Thursday granted an indefinite delay of an antitrust trial slated to start next week, allowing Allergan PLC to appeal the certification of a class of unions and grocers who claim the company and a subsidiary manipulated the market with a monopolistic hard switch of available anti-inflammatory drugs.
Allergan and Warner Chilcott on Tuesday asked a Massachusetts federal court for an order stating that lists of prescription drugs covered by insurers are admissible evidence during an antitrust trial brought by a class of organizations that purchased ulcerative colitis drug Asacol.
Attorneys for Allergan PLC and subsidiary Warner Chilcott Ltd. asked a Massachusetts federal judge on Monday to block a group of unions and grocers from replacing witness testimony with recorded depositions in the antitrust class action set to go to trial in two weeks.
A class of end purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs urged a Massachusetts federal court Monday not to certify a causation issue, saying they’ve adequately argued that the companies’ alleged wrongdoing caused them harm.
Allergan PLC and several related companies lost their bid to exit an antitrust suit by end purchasers of an ulcerative colitis drug as a Massachusetts federal judge on Thursday denied their attempt to kill the claims and granted certification to a class of buyers.
Attorneys for direct purchasers who recently struck a $15 million deal in a suit accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their drug Asacol urged a Massachusetts federal judge Thursday to hand them almost $5.46 million in fees and expenses, arguing that they are asking for significantly less than the $8.3 million worth of work they did in the case.
Allergan subsidiary Warner Chilcott has told a Massachusetts federal court that pulling its Asacol ulcerative colitis drug off the market pursuant to a federal safety order can’t be considered anti-competitive conduct, urging the court to grant it a quick win in an antitrust lawsuit.
A Massachusetts federal judge Thursday granted preliminary approval to a $15 million settlement that would end claims brought by direct purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs.
Allergan shouldn’t be able to get competitor Shire’s most sensitive data to beat back antitrust allegations over an ulcerative colitis drug, Shire told a federal court in Massachusetts on Tuesday.